{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:01:16Z","timestamp":1769504476719,"version":"3.49.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cpcardiol.2023.102057","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T11:01:09Z","timestamp":1693047669000},"page":"102057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"PB","title":["Exploring Transthyretin Amyloid Cardiomyopathy: A Comprehensive Review of the Disease and Upcoming Treatments"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-4299","authenticated-orcid":false,"given":"Hritvik","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali Mohan Rama Krishna","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit Chandra","family":"Dey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Shakhatreh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarbagya","family":"Manandhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purushottam","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeeha Subhan","family":"Waleed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rukesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biki Kumar","family":"Sah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rukam","family":"Mahawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.102057_bib0001","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0002","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0003","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/hrt.2009.190405","article-title":"Amyloid diseases of the heart: assessment, diagnosis, and referral","volume":"97","author":"Dubrey","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0006","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0007","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0008","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0010","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0011","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1586\/erc.10.41","article-title":"Cardiac amyloidosis: an approach to diagnosis and management","volume":"8","author":"Halwani","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0012","first-page":"e350","volume":"117","author":"Epstein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0013","doi-asserted-by":"crossref","first-page":"11793","DOI":"10.1016\/S0021-9258(17)39100-7","article-title":"Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat","volume":"260","author":"Soprano","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0014","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/lt.21817","article-title":"Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients\u2019 survival","volume":"15","author":"Okamoto","year":"2009","journal-title":"Liver Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.cpcardiol.2023.102057_bib0015","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Martinez-Naharro","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0017","series-title":"StatPearls","article-title":"Transthyretin amyloid cardiomyopathy (ATTR-CM) [Internet]","author":"Jain","year":"2023"},{"issue":"7 Suppl","key":"10.1016\/j.cpcardiol.2023.102057_bib0018","first-page":"S107","article-title":"Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges","volume":"23","author":"Gertz","year":"2017","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0019","series-title":"GeneReviews\u00ae","article-title":"Hereditary transthyretin amyloidosis [Internet]","author":"Sekijima","year":"1993"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0020","first-page":"1166.e1","article-title":"Wild-type transthyretin cardiac amyloidosis: novel insights from advanced imaging","volume":"32","author":"Narotsky","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40119-020-00205-3","article-title":"Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"10","author":"Kroi","year":"2021","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0022","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/biomedicines10081906","article-title":"The journey of human transthyretin: synthesis, structure stability, and catabolism","volume":"10","author":"Sanguinetti","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0023","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.3390\/ijms22094429","article-title":"Transthyretin misfolding, a fatal structural pathogenesis mechanism","volume":"22","author":"Si","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0024","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants, 2003","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2023.102057_bib0025","first-page":"39","article-title":"Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction","volume":"8","author":"Ton","year":"2014","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0026","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/labinvest.3780116","article-title":"Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation","volume":"80","author":"Sousa","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0027","doi-asserted-by":"crossref","first-page":"21998","DOI":"10.1074\/jbc.M602302200","article-title":"Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy","volume":"281","author":"Teixeira","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0028","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/path.2224","article-title":"Impairment of the ubiquitin-proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy","volume":"213","author":"Santos","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0029","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000466701","article-title":"Cytotoxic effects of transthyretin aggregates in an epidermoid cell line","volume":"84","author":"Fong","year":"2017","journal-title":"Pathobiology"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0030","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0031","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cardfail.2016.10.008","article-title":"Transthyretin cardiac amyloidosis in older Americans","volume":"22","author":"Brunjes","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0032","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0033","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","article-title":"Diagnosis of transthyretin amyloid cardiomyopathy","volume":"9","author":"Hafeez","year":"2020","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0034","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cpf.12715","article-title":"Combining ECG and echocardiography to identify transthyretin cardiac amyloidosis in heart failure","volume":"41","author":"L\u00f6fbacka","year":"2021","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0035","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0036","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12350-013-9803-2","article-title":"Nuclear imaging modalities for cardiac amyloidosis","volume":"21","author":"Bokhari","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0037","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.mpdhp.2022.02.001","article-title":"Cardiac amyloidosis: a clinical and pathological review","volume":"28","author":"Maleszewski","year":"2022","journal-title":"Diagn. Histopathol."},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0038","doi-asserted-by":"crossref","first-page":"21","DOI":"10.36628\/ijhf.2022.0032","article-title":"Lifestyle modification in heart failure management: are we using evidence-based recommendations in real world practice?","volume":"5","author":"Camafort","year":"2023","journal-title":"Int J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0039","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007779","article-title":"Heart failure medical management in 2020: searching for the right polypharmacy","volume":"13","author":"Denny","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0040","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1161\/CIRCRESAHA.118.313568","article-title":"Medical therapy for heart failure caused by ischemic heart disease","volume":"124","author":"Elgendy","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0041","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.3390\/nu13093029","article-title":"Neck circumference as a predictor of metabolic syndrome in Koreans: a cross-sectional study","volume":"13","author":"Kim","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0042","series-title":"StatPearls","article-title":"Antiarrhythmic medications [Internet]","author":"King","year":"2023"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0043","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.mayocp.2021.08.006","article-title":"Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy","volume":"97","author":"Barge-Caballero","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0044","article-title":"Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary center experience","volume":"9","author":"Razvi","year":"2023","journal-title":"Front Cardiovasc Med [Internet]"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/164_2019_331","article-title":"Immunosuppressants in organ transplantation","volume":"261","author":"T\u00f6nshoff","year":"2020","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0046","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0047","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamacardio.2019.5233","article-title":"Tafamidis - a pricey therapy for a not-so-rare condition","volume":"5","author":"Gurwitz","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0048","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0049","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0051","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0052","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0053","doi-asserted-by":"crossref","first-page":"28932","DOI":"10.1074\/jbc.M115.659912","article-title":"Uncovering the mechanism of aggregation of human transthyretin","volume":"290","author":"Saelices","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0054","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ejhf.1695","article-title":"Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?","volume":"22","author":"M\u00fcller","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0055","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ehf2.13961","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0056","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0057","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0058","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","article-title":"Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups","volume":"16","author":"Rintell","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0059","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2016.09.987","article-title":"Val122Ile mt-ATTR has a worse survival than wt-ATTR cardiac amyloidosis","volume":"69","author":"Singh","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2023.102057_bib0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/13506129.2019.1582018","article-title":"Cardiovascular autonomic functions in late-onset hereditary transthyretin amyloidosis with Val30Met mutation","volume":"26","author":"Nakamura","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0061","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0062","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0063","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0064","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0065","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0066","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0067","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10741-020-10062-w","article-title":"Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis","volume":"26","author":"Bistola","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0068","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/10600280211000351","article-title":"Transthyretin amyloid cardiomyopathy-current and future therapies","volume":"55","author":"Yadav","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0069","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/pharmaceutics15041129","article-title":"Transthyretin stabilizers and seeding inhibitors as therapies for amyloid transthyretin cardiomyopathy","volume":"15","author":"Morfino","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0070","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3390\/jcm11082148","article-title":"Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges","volume":"11","author":"Tsch\u00f6pe","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2023.102057_bib0071","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2018.09.007","article-title":"Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR","volume":"120","author":"Saelices","year":"2018","journal-title":"Neurobiol. Dis."}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623004747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623004747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:17:52Z","timestamp":1758939472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623004747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0146280623004747"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102057","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring Transthyretin Amyloid Cardiomyopathy: A Comprehensive Review of the Disease and Upcoming Treatments","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"102057"}}